^
BIOMARKER:
HER-2 L755S
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 L755S
|
HER2 Negative Breast Cancer
|
HER-2 L755S
|
HER2 Negative Breast Cancer
|
neratinib Sensitive: C2 – Inclusion Criteria
|
neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
HER-2 L755S
|
Triple Negative Breast Cancer
|
HER-2 L755S
|
Triple Negative Breast Cancer
|
neratinib Sensitive: C4 – Case Studies
|
neratinib Sensitive: C4 – Case Studies
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
tucatinib Resistant: D – Preclinical
|
tucatinib Resistant: D – Preclinical
|
HER-2 L755S
|
CRC
|
HER-2 L755S
|
CRC
|
panitumumab Resistant: D – Preclinical
|
panitumumab Resistant: D – Preclinical
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Resistant: D – Preclinical
|
trastuzumab + tucatinib Resistant: D – Preclinical
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
neratinib Resistant: D – Preclinical
|
neratinib Resistant: D – Preclinical
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
HER-2 L755S
|
HER2 Positive Breast Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
HER-2 L755S
|
Gastric Cancer
|
HER-2 L755S
|
Gastric Cancer
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 L755S
|
CRC
|
HER-2 L755S
|
CRC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|
HER-2 L755S
|
NSCLC
|
HER-2 L755S
|
NSCLC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 L755S
|
Gastric Cancer
|
HER-2 L755S
|
Gastric Cancer
|
CL-387785 Sensitive: D – Preclinical
|
CL-387785 Sensitive: D – Preclinical
|
HER-2 L755S
|
Gastric Cancer
|
HER-2 L755S
|
Gastric Cancer
|
WZ4002 Sensitive: D – Preclinical
|
WZ4002 Sensitive: D – Preclinical
|
HER-2 L755S
|
CRC
|
HER-2 L755S
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
WZ4002 Sensitive: D – Preclinical
|
WZ4002 Sensitive: D – Preclinical
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
AEE788 Sensitive: D – Preclinical
|
AEE788 Sensitive: D – Preclinical
|
HER-2 L755S
|
Breast Cancer
|
HER-2 L755S
|
Breast Cancer
|
CL-387785 Sensitive: D – Preclinical
|
CL-387785 Sensitive: D – Preclinical
|
HER-2 L755S
|
HER2 Negative Breast Cancer
|
HER-2 L755S
|
HER2 Negative Breast Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
HER-2 L755S
|
Gastric Cancer
|
HER-2 L755S
|
Gastric Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
HER-2 L755S
|
Gastric Cancer
|
HER-2 L755S
|
Gastric Cancer
|
AEE788 Sensitive: D – Preclinical
|
AEE788 Sensitive: D – Preclinical
|
